Loading clinical trials...
Loading clinical trials...
A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Conditions
Interventions
Nivolumab
Everolimus
Locations
168
United States
Local Institution - 0182
Fayetteville, Arkansas, United States
UCSD Moores Cancer Center
La Jolla, California, United States
Local Institution - 0024
Los Angeles, California, United States
University Of Southern California
Los Angeles, California, United States
Cedars Sinai Medical Center
Los Angeles, California, United States
Ucsf Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Start Date
October 9, 2012
Primary Completion Date
May 6, 2015
Completion Date
July 19, 2021
Last Updated
August 9, 2022
Lead Sponsor
Bristol-Myers Squibb
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions